TIGERMED to Seek Shareholder Approval for A-Share Repurchase at 9 June 2026 EGM

Bulletin Express
05/19

Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) has issued a proxy form outlining matters to be decided at its Second Extraordinary General Meeting (EGM) scheduled for 3:00 p.m. on 9 June 2026 at the company’s Hangzhou headquarters.

The sole agenda item is a special resolution authorising the repurchase of A-shares via centralized price bidding. Key elements up for approval include:

• Purpose and intended use of the repurchased shares.

• Confirmation that statutory and regulatory conditions for the buyback are met.

• Repurchase method, share class, quantity, and proportion relative to total share capital.

• Total capital allocation, funding source, and pricing framework or range.

• Duration of the repurchase period.

• A mandate empowering the Board to handle all procedural matters related to the buyback.

Shareholders may appoint the EGM chairman or another proxy to vote. Completed proxy forms, together with any power of attorney, must reach the H-share registrar (Tricor Investor Services Limited, Hong Kong) at least 24 hours before the meeting. Attendance requires presentation of identity documents.

Completion and return of the proxy form do not preclude shareholders from attending and voting in person. All times reference Hong Kong local time.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10